The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies
Abstract
The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging. However, most anti-diabetic drugs cannot be used in patients with hepatic dysfunction, renal disease, and heart disease, which makes pharmacological therapy of type 2 diabetes complicated. Despite continued introduction of novel agents, the search for an ideal drug that is useful as both a hypoglycemic agent and to reduce diabetes-related complications remains elusive. Berberine is an isoquinoline alkaloid extract that has shown promise as a hypoglycemic agent in the management of diabetes in animal and human studies. Mechanistic studies have revealed beneficial effects of berberine on diabetes-related complications. Although there have been few clinical reports of the anti-diabetic effects of berberine, little documentation of adverse effects in humans positions it as a potential candidate drug to treat type 2 diabetes. In the present review, the anti-diabetic mechanism of berberine, its effect on diabetes-related complications, and its recent use in human clinical studies is highlighted. In addition, we summarize the different treatments for type 2 diabetes in adults and children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Adipocyte differentiation from the inside out
Rosen, E. D., & MacDougald, O. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2066 · Cited by 2,607
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573
Turner, N., Li, J.-Y., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., et al. (2008) · Diabetes · doi:10.2337/db07-1552 · Cited by 535
NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis
Gray, S. P., Di Marco, E., Okabe, J., Szyndralewiez, C., Heitz, F., Montezano, A. C., de Haan, J. B., Koulis, C., El-Osta, A., Andrews, K. L., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.132159 · Cited by 386
Gomes, A. P., Duarte, F. V., Nunes, P., Hubbard, B. P., Teodoro, J. S., Varela, A. T., Jones, J. G., Sinclair, D. A., Palmeira, C. M., & Rolo, A. P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.008 · Cited by 159 · cited 1×
“dysfunction induced by high fat diet and hyperglycemia in skeletal muscle, in part due to an increase inmitochondrial biogenesis, and this wasmediated by increased expression of sirtuin 1 (SIRT1), a deacetylase with multiple biological activities and antioxidant activity (Gomes et al. 2012).”
BackgroundCardiovascular effects of berberine in patients with severe congestive heart failure
Marin ‐ NETO, J. A., Maciel, B. C., Secches, A. L., & Gallo, L. (1988) · Clinical Cardiology · doi:10.1002/clc.4960110411 · Cited by 128
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion
Pérez-Rubio, K. G., González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., & Espinel-Bermúdez, M. C. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0183 · Cited by 113
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Derosa, G., D'Angelo, A., Bonaventura, A., Bianchi, L., Romano, D., & Maffioli, P. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.776037 · Cited by 112
Cited by
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms
Xu, L., Li, Y., Dai, Y., & Peng, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.015 · Cited by 452
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes
Wen, L., & Duffy, A. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.240754 · Cited by 412
The strategies and techniques of drug discovery from natural products
Zhang, L., Song, J., Kong, L., Yuan, T., Li, W., Zhang, W., Hou, B., Lu, Y., & Du, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107686 · Cited by 313
Wang, L.-L., Guo, H.-H., Huang, S., Feng, C.-L., Han, Y.-X., & Jiang, J.-D. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.05.004 · Cited by 58
Metadata
- Authors
- Chang, W., Chen, L., & Hatch, G. M.
- Venue
- Biochemistry and Cell Biology
- Publisher
- Canadian Science Publishing
- Published
- 2015-10
- Volume
- 93
- Issue
- 5
- Pages
- 479-486
- ISSN
- 0829-8211 (ISSN-L)
- 1208-6002
- OpenAlex
- W2119922737
- Cited by
- 158
- References
- 11
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. https://app.cochat.ai/papers/10.1139/bcb-2014-0107
- The paper
- Chang, W., Chen, L., & Hatch, G. M. (2015). Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2014-0107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.